ММВБ 2 739 -0,7%  Nasdaq 7 797 -0,5%  Биткойн 9 283 4,9%  USD/RUB 64,4020 0,0% 
РТС 1 341 -0,4%  S&P500 2 887 -0,2%  Нефть 62,0 1,1%  EUR/RUB 72,1755 -0,9% 
Dow 26 090 -0,1%  FTSE100 7 346 -0,3%  Золото 1 333 -0,7%  EUR/USD 1,1265 -0,1% 

Курс акций Celgene [ISIN: US1510201049]

купить
продать

Celgene Corp. - Профиль

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Акционеры

Название Доля (%)
Freefloat99,79
The Vanguard Group, Inc.7,40
BlackRock Fund Advisors5,44
SSgA Funds Management, Inc.4,32
Fidelity Management & Research Co.2,18
Orbis Investment Management Ltd.1,97
Pentwater Capital Management LP1,39
Geode Capital Management LLC1,33
Northern Trust Investments, Inc.(Investment Management)1,28
Adage Capital Management LP1,26
Farallon Capital Management LLC1,20
Norges Bank Investment Management1,07
D. E. Shaw & Co. LP1,04
Invesco Capital Management LLC1,04
Abrams Capital Management LP0,96

Адрес

86 Morris Avenue, 07901 Summit
а/я:
Телефон: 19086739000
Факс:
Вэб: http://www.celgene.com

Менеджмент

David V. Elkins, MBA
CFO, Principal Accounting Officer & Executive VP
Mark J. Alles
Chairman, President, CEO & COO
Toni-Ann Citera
Chief Compliance Officer & Senior Vice President
Peter N. Kellogg, MBA
Chief Corporate Strategy Officer & Executive VP
Aijaz Tobaccowalla
Chief Digital & Information Officer, Senior VP
Jay T. Backstrom, MD
Chief Medical Officer
Kristen M. Hege, MD
Corporate VP-Translational Development
Hans E. Bishop
Director
Richard H. Bagger
EVP-Corporate Affairs & Strategic Market Access
Joseph Hand
EVP-Global Human Resources & Corporate Services
Joanne T. Beck, PhD
EVP-Pharmaceutical Development & Operations
Anjan G. Thakurta
Executive Director-Translational Development
Jonathan Prim Biller
Executive Vice President & General Counsel
Carrie Smith Cox
Independent Director
Patricia A. Hemingway Hall
Independent Director
John H. Weiland, MBA
Independent Director
Ernest Mario, PhD
Independent Director
Richard W. Barker, PhD
Independent Director
James J. Loughlin, CPA
Independent Director
Michael W. Bonney
Independent Director
Julia A. Haller, MD
Independent Director
Michael D. Casey
Lead Independent Director
Alise Reicin, MD
President-Global Clinical Development
Terrie Curran
President-Global Inflammation & Immunology
Nadim Ahmed
President-Hematology & Oncology
Rupert J. Vessey, PhD
President-Research & Early Development
Catherine Cantone
Senior Director-Corporate Communications
Catherine B. Elflein MBA, CPA
Senior Director-Risk Management
Michael Pourdehnad
Senior Director-Translational Development
Jennifer Dudinak PharmD
Senior Vice President-Global Regulatory Affairs
Patrick E. Flanigan III
Treasury & Senior VP-Investor Relations
Philippe Martin
VP Project Leadership & Project Management
Robert M. Plenge MD, PhD
VP-R&D, Head-Inflammation & Immunology
Ho Sung Cho, PhD
Vice President-Biotherapeutics

Добавить или редактировать инструмент